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Prompt laboratory reporting of tuberculosis (TB) test results is necessary for TB control. To understand the
extent of and factors contributing to laboratory reporting delays and the impact of reporting delays on
initiation of treatment of TB patients, we analyzed data from 300 consecutive culture-positive TB cases
reported in four California counties in 1998. Laboratory reporting to the specimen submitter was delayed for
26.9% of smear-positive patients and 46.8% of smear-negative patients. Delays were associated with the type of
laboratory that performed the testing and with delayed transport of specimens. Referral laboratories (public
health and commercial) had longer median reporting time frames than hospital and health maintenance
organization laboratories. Among patients whose treatment was not started until specimens were collected,
those with delayed laboratory reporting were more likely to have delayed treatment than patients with no
laboratory reporting delays (odds ratio [OR] of 3.9 and 95% confidence interval [CI] of 1.6 to 9.7 for
smear-positive patients and OR of 13.1 and CI of 5.3 to 32.2 for smear-negative patients). This relation
remained after adjustment in a multivariate model for other factors associated with treatment delays (adjusted
OR of 25.64 and CI of 7.81 to 83.33 for smear-negative patients). These findings emphasize the need to reduce
times of specimen transfer between institutions and to ensure rapid communication among laboratories, health
care providers, and health departments serving TB patients.
nance organization (HMO), and hospital-based laboratories
are all involved in performing TB tests.

Timely laboratory reporting of tuberculosis (TB) is important for prompt initiation of appropriate medical therapy for
TB patients and rapid public health response. National guidelines and regulations in 39 states specify that laboratories performing TB diagnostic tests and drug susceptibility tests should
report test results to the specimen submitters and to health
departments within specific time frames (4, 5). Although national surveys of laboratory practice have documented an increase in the number of laboratories that report TB test results
within the time frames recommended by the Centers for Disease Control and Prevention and the Association of Public
Health Laboratories (2, 8, 10), previous publications have not
documented the analysis of factors associated with delayed
reporting. Also, the role that laboratory reporting may play in
treatment initiation has not been documented in studies of
treatment initiation delays. To describe laboratory reporting
time frames and delays and how these delays may impact
timely initiation of treatment for TB patients, we performed
this study. This patient-based study examines the time frames
for laboratory reporting of TB test results from a cohort of
culture-positive TB patients from California in 1998, describes
factors that contribute to delays in reporting, and analyzes the
association between delayed reporting of laboratory findings of
TB and delays in the initiation of anti-TB therapy. The study
was conducted in a state where private, public, health mainte-

MATERIALS AND METHODS
Study population. The study population and data collection have been described previously (11). For each of 300 culture-confirmed TB cases reported to
the TB control programs in San Francisco, Santa Clara, Los Angeles, and
Riverside counties in 1998, three to six specimens were subjected to acid-fast
bacillus (AFB) smear microscopy, culture growth, M. tuberculosis complex identification, and drug susceptibility testing. The earliest reported positive result was
recorded for each test. Patient data from the Report of Verified Case of Tuberculosis (RVCT), the national TB surveillance case report, were examined.
Study variables. The submitter reporting time frame was defined as the time
between the date of specimen collection and the date that the laboratory reported the first evidence of M. tuberculosis to the specimen submitter. The
transport time frame was defined as the time between the date of specimen
collection and the date the specimen was received in the laboratory that performed the applicable TB tests. The local health department (LHD) reporting
time frame was defined as the time between the date that the first evidence of M.
tuberculosis was reported to the specimen submitter and the date that the test
result was reported to the LHD. The treatment initiation time frame was defined
as the time between the date of specimen collection and the date that anti-TB
therapy was initiated.
The first evidence of M. tuberculosis in a specimen is the presence of AFB on
smear microscopy; for patients with AFB smear-negative specimens, the first
evidence of M. tuberculosis is the presence of AFB-positive growth in a culture or
the identification of M. tuberculosis complex in a growing culture.
The LHD reporting time frame was calculated for only those patients served
by non-public health laboratories, because public health laboratories are considered to be part of the LHD. Patients excluded from LHD reporting time frame
calculations were those for whom laboratory reporting to the LHD occurred
before laboratory reporting to the submitter, those with missing dates, and those
with no evidence of laboratory reporting to the LHD (79 AFB smear-positive
patients and 59 AFB smear-negative patients).
Delayed reporting and treatment initiation time frames were defined as time
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frames that exceeded the median (13). Overall, the medians for submitter reporting time frames met the Centers for Disease Control and Prevention recommendations (5). Existing guidelines do not recommend a particular time
frame for treatment initiation but state that treatment should be initiated
promptly when suspicion of tuberculosis is high or the patient is seriously ill with
a disorder that may possibly be tuberculosis (6). Thus, delayed treatment initiation was defined as a time frame that exceeded the median based on the
precedent set by a surveillance study on delays in diagnosis and treatment (13).
Delayed transport occurred if the time between specimen collection and receipt
in the laboratory performing the testing exceeded one day (2). Delayed LHD
reporting time frames were greater than one working day (15).
Participating laboratories were categorized into four types: public health laboratories, hospital laboratories, HMO laboratories (the state’s two regional laboratories that served patients from multiple hospitals of a staff-model HMO
health care plan), and commercial laboratories (private laboratories that were
not directly associated with hospitals, public health institutions, or HMOs).
Analyses. Medians, means, and ranges of the above-described time frames
were calculated separately for AFB smear-positive and AFB smear-negative
patients and stratified by laboratory type. Comparisons were made using nonparametric methods. The odds ratios (ORs) and relative risks of delays in
treatment for those with and without reporting delays were determined. For
concise presentation, the ORs are shown in tabular form (see Table 2), but the
relative risks are stated in the text only.
Pearson’s chi-square or Fisher’s exact test was used to determine the association of disease and demographic characteristics with treatment initiation delays.
Multivariate analyses were performed with selected variables using forward logistic regression. Variables were included if, when adjusting for them, CochranMantel-Haenszel statistics showed an association of submitter reporting delays
and treatment initiation delays and if the variables were associated with treatment delay in previous studies.
All statistical analyses were performed using SAS (version 8.2; SAS Institute,
Cary, N.C.).

RESULTS
Study population and laboratories. Fifty-five laboratories
were involved in TB testing for the patient population, including seven public health laboratories, two HMO laboratories,
eleven commercial laboratories, and thirty-five hospital laboratories. Fifty-four laboratories participated in the study; one
laboratory declined to participate (11).
Of the 300 patients in the study sample, 32 (10.7%) were
excluded from the analyses because they had unknown AFB
smear microscopy results, leaving 268 patients with known
AFB smear results. The characteristics of these 268 patients
were as follows: 163 (60.8%) were male, 69 (25.7%) were $65
years old, 130 (48.5%) were reported as being of the Asian or
Pacific Islander race, 195 (72.8%) were foreign born, and 13
(4.9%) were homeless during the year previous to diagnosis.
Disease characteristics for this population included the following: 225 (84%) had pulmonary TB, 135 (50.4%) had AFB
smear-positive specimens, 224 (83.6%) had abnormal chest
radiographs, 59 (26.3%) had cavitation on chest radiographs,
28 (10.4%) had M. tuberculosis strains that were resistant to
isoniazid, rifampin, or ethambutol, and 6 (2.2%) had strains
that were multidrug-resistant (i.e., resistant to at least isoniazid
and rifampin). Fourteen (5.2%) patients in this population had
AIDS. Excluded patients with unknown AFB smear results did
not differ from the study population by demographic or clinical
characteristics (data not shown).
Among the 135 AFB smear-positive and 133 AFB smearnegative patients, 31 AFB smear-positive and 22 AFB smearnegative patients were excluded from further analyses because
TB treatment was initiated prior to specimen collection or
because of missing dates. These excluded patients had demographic and clinical characteristics similar to those of the pa-
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TABLE 1. Time frames for reporting to specimen submitter and
initiating treatment
Patient group

AFB smear positive
All
With delaysa
Tested in hospital lab
Tested in public health lab
Tested in commercial lab
Tested in HMO lab
AFB smear negative
All
With delaysb
Tested in hospital lab
Tested in public health lab
Tested in commercial lab
Tested in HMO lab

No. of
patients

104
63
17
10
14
111
49
19
23
20

Time frame median (range)c
Submitter
reporting

Treatment
initiation

1.0 (0–35)
2.0 (2–35)
1.0 (0–14)
2.0 (0–35)
2.0 (1–3)
1.0 (0–5)

1.0 (0–70)
4.0 (2–70)
1.0 (0–16)
2.0 (0–48)
4.0 (0–70)
2.5 (0–20)

21.0 (9–143)
28.5 (22–143)
20.0 (9–143)
22.0 (11–64)
28.0 (18–60)
18.5 (10–29)

22.0 (0–145)
33.5 (23–145)
20.0 (0–145)
20.0 (0–78)
31.0 (0–75)
21.0 (1–62)

a
Number of AFB smear-positive patients with delays in submitter reporting,
28; number with delays in treatment initiation, 42.
b
Number of AFB smear-negative patients with delays in submitter reporting,
52; number with delays in treatment initiation, 52.
c
Values are numbers of days.

tient population included in the study (data not shown). The
remaining 104 AFB smear-positive and 111 AFB smear-negative patients were included in the final analyses.
Submitter reporting time frames and factors contributing to
delayed reporting for AFB smear-positive patients. The majority of patients with AFB smear-positive specimens had
smear microscopy performed in hospital laboratories (60.6%).
A much lower percentage of patients had smear microscopy
performed by public health, HMO, and commercial laboratories (23.7, 11.9, and 8.9%, respectively).
The median time from the date of specimen collection to the
date that the laboratory reported results to the specimen submitter (submitter reporting time frame) was 1.0 day (mean,
1.88 days; range, 0 to 35 days) for AFB smear-positive patients
but was longer for specimens tested in public health and commercial laboratories than that for specimens tested in hospital
and HMO laboratories (P , 0.0001) (Table 1). Overall, the 28
patients with delayed submitter reporting (26.9%) had a median reporting time frame of 2.0 days (mean, 5.0 days).
To determine whether the time between specimen collection
and specimen receipt in the laboratory (transport time frame)
was associated with delays in reporting positive AFB smear
results, these time frames were calculated for patients tested at
each laboratory type. Transport time frames were longer for
AFB smear-positive specimens tested in public health and
commercial laboratories than for specimens tested in hospital
and HMO laboratories (median times: for public health laboratories, 1.0 day; for commercial laboratories, 1.5 days; for
hospital and HMO laboratories, 0 days; P 5 0.0002). In addition, patients having AFB smear-positive specimens that took
longer than 1 day to arrive in the laboratory that performed the
AFB smear microscopy were 5.9 times more likely to have
delayed laboratory reporting to the specimen submitter than
patients with specimens that arrived in the laboratory within 1
day of collection (P , 0.0001). Delayed transport was only one
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of potentially many factors contributing to submitter reporting
delays; 14 of 27 (51.9%) specimens having reporting delays
were received in the testing laboratory within 1 day of specimen collection. Additional factors contributing to submitter
reporting delays for AFB smear-positive patients were not
explored in this study.
Submitter reporting time frames and factors contributing to
delayed reporting for AFB smear-negative patients. Laboratories reported the first indication of the presence of M. tuberculosis in AFB smear-negative patients as either the presence
of AFB in a growing culture (60.4%) or the positive identification of M. tuberculosis complex in a culture (39.6%). Hospital, commercial, HMO, and public health laboratories reported
the first indications of M. tuberculosis to specimen submitters
for 44.1, 20.7, 18.0, and 17.1%, respectively, of AFB smearnegative patients.
The median submitter reporting time frame was 21.0 days
(mean, 25.35 days; range, 9 to 143 days) for AFB smearnegative patients, but specimens and cultures tested in commercial laboratories had longer reporting time frames than
specimens and cultures tested in public health, HMO, and
hospital laboratories (P 5 0.0005) (Table 1). The 52 patients
with delayed reporting (46.8%) had a median submitter reporting time frame of 28.5 days (mean, 35.3 days).
After being tested by AFB microscopy, specimens from the
111 AFB smear-negative patients were processed in one of
three ways: 92 patients (82.9%) had reports of the first evidence of TB made by the same laboratory that performed the
AFB smear microscopy, 15 patients (13.5%) had specimens
referred to another laboratory before reports were made, and
4 patients (3.6%) had specimens that were inoculated into
culture before they were referred to another laboratory for
identification of M. tuberculosis complex. Specimens that were
first inoculated into culture before referral had longer reporting time frames (mean, 31.5 days; median, 28.5 days) than
specimens that were directly referred (mean, 23.9 days; median, 21.0 days) and nonreferred specimens (mean, 25.3 days;
median, 21.0 days) (P 5 0.48). There was not enough power in
this study to determine the extent to which referral practices
may have contributed to delays. However, transport times for
patient specimens and cultures that were referred from one
laboratory to another were longer (mean, 5.7 days; median, 0.5
day) than for patient specimens that were not referred between
laboratories (mean, 1.27 days; median, 0.0 days) (P 5 0.047).
In addition, patients with AFB smear-negative specimens that
took longer than 1 day to reach the laboratory that performed
the culture and/or identification of M. tuberculosis complex
were 2.5 times more likely to have delayed laboratory reporting
than patients with specimens or cultures that arrived in the
laboratory within 1 day of collection (P 5 0.001). Again, delayed transport was only one of potentially many factors contributing to submitter reporting delays for AFB smear-negative
patients: 38 of 46 (83%) specimens having reporting delays
arrived in the laboratory within 1 day of the specimen collection.
Another factor that contributed to submitter reporting delays for AFB smear-negative patients was the practice of reporting the first indication of TB as positive identification of M.
tuberculosis complex in a culture, rather than as the presence of
AFB in a growing culture. Reporting positive identification of

REPORTING DELAYS AND TREATMENT DELAYS

4211

M. tuberculosis complex as the first indication of TB (mean,
32.8 days; median, 27.0 days) was 2.9 times more likely to be
delayed than reporting a growing culture as the first indication
of TB for AFB smear-negative patients (mean, 20.5 days; median, 19.0 days) (P , 0.0001).
Laboratory reporting to LHD. Reporting TB test results to
the specimen submitter is not the only reporting requirement
of laboratories. In California and many other states, laboratories are required to report TB test results to the appropriate
LHD within 1 working day of reporting to the specimen submitter.
Public health laboratories are part of LHDs, and their patients were not included in the following analyses. Non-public
health laboratories tested 87 AFB smear-positive patients; 79
of these fit the inclusion criteria for calculating medians,
means, and ranges of LHD reporting times (see Materials and
Methods). The median LHD reporting time frame for these 79
AFB smear-positive patients was 0 working days (mean, 1.6
days; range, 0 to 35 days). Laboratory reports to the LHD for
12 of 87 (13.8%) AFB smear-positive patients were delayed,
i.e., the reporting time frame was greater than the legal requirement of 1 working day from notification of the specimen
submitter. Of these delayed reports, 66.7% (n 5 8) were made
by hospital laboratories.
Non-public health laboratories tested 92 AFB smear-negative patients; 59 of these fit the inclusion criteria for calculating
medians, means, and ranges of LHD reporting times. The
median LHD reporting time frame for these 59 AFB smearnegative patients was 0 days (mean, 1.1 days; range, 0 to 34
days); six (6.5%) reports were delayed. Of these delayed reports, 83.3% (n 5 5) were made by HMO laboratories. Eighteen AFB smear-negative patients served by non-public health
laboratories (19.6%) had no evidence of laboratory reporting
to the LHD; hospital, HMO, and commercial laboratories performed the TB testing for seven, six, and five of these AFB
smear-negative patients, respectively.
Laboratory reporting and treatment initiation. A total of
40.4% of AFB smear-positive patients and 46.8% of AFB
smear-negative patients had treatment initiation delays (Table
1). Patients whose positive smear results were reported to the
submitter more than 1 day after specimen collection were twice
as likely to have delays initiating therapy than patients whose
positive smear results were reported within 1 day (OR 5 3.9)
(Table 2). Univariate analyses were performed to detect association of treatment delays for AFB smear-positive patients
with demographic or disease characteristics; associations with
these factors were not found. For AFB smear-negative patients, those whose first evidence of TB was reported to the
submitter more than 21 days after specimen collection were 3.8
times more likely to have delays initiating therapy than patients
whose first evidence of TB was reported within 21 days, (unadjusted OR 5 4.23) (Table 2). The association of delayed
laboratory reporting to the specimen submitter and delayed
treatment remained, even after adjusting for older age and
normal chest radiograph results (adjusted OR 5 25.64) (Table
2), factors that were previously shown in some TB patient
populations to be associated with treatment initiation delays
(9, 12).
Although delayed laboratory reporting to the submitter was
a factor contributing to delayed treatment, many patients with
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TABLE 2. ORs for factors associated with treatment initiation delaysa
No. of patients (%)

No. of patients with
treatment initiation delays
(%)

AFB smear positive
Report to specimen
submitter in .1 day
Report to specimen
submitter in #1 day

104
28 (26.9)

42 (40.4)
18 (64.3)

3.90 (1.57–9.71)

76 (73.1)

24 (31.6)

Ref.

AFB smear negative
$65 yr old
,65 yr old
Chest radiograph normalc
Chest radiograph abnormalc
Report to specimen
submitter in .21 days
Report to specimen
submitter in #21 days

111
39 (35.1)
72 (64.9)
23 (21.1)
86 (78.9)
52 (46.8)

52 (46.8)
27 (69.2)
25 (34.7)
14 (60.9)
38 (44.2)
40 (76.9)

4.23 (1.83–9.75)
Ref.
1.96 (0.77–5.03)
Ref.
13.06 (5.28–32.25)

59 (53.2)

12 (20.3)

Ref.

Patient group and factor

a
b
c

Unadjusted OR
(95% CI)

Adjusted ORb (95% CI)

Not applicable

5.88 (1.86–18.52)
Ref.
6.71 (1.70–26.3)
Ref.
25.64 (7.81–83.33)

CI, confidence interval; Ref., reference group.
Adjusted model includes age, chest radiograph results, and submitter reporting time frame.
The total number of patients with normal and abnormal chest radiograph was 109, because 2 had missing chest X-ray data.

delayed treatment had timely submitter reporting (31.6% of
AFB smear-positive and 20.3% of AFB smear-negative patients). In addition, AFB smear-positive results for 87.5% of
these patients with timely submitter reporting but delayed
treatment were reported to the LHD within the required 1-day
time frame. These findings suggest that further steps could
have been taken by the LHD to ensure prompt treatment
initiation for these AFB smear-positive patients. On the other
hand, only 41.7% of the AFB smear-negative patients with
timely submitter reporting and delayed treatment were reported to the LHD within the required 1-day time frame. Thus,
LHDs may not have known of the existence of more than half
of this subset of AFB smear-negative patients in time to ensure
rapid treatment initiation.
DISCUSSION
Health care providers received delayed laboratory reports of
the first evidence of TB for 27% of AFB smear-positive patients, the most infectious patients, in this population. Reporting delays were associated with delays in the transport of specimens from the collection site to the laboratory performing the
smear microscopy, and, consequently, were also associated
with laboratory type, with public health and commercial laboratories having longer median reporting times than hospital
and HMO laboratories. These data suggest that public health
interventions aimed at facilitating the rapid transport of specimens to public health and commercial laboratories would
reduce the number of nonhospitalized patients with delayed
treatment initiation attributable to delayed laboratory reporting. But not all reporting delays were attributable to transport
delays. To identify additional public health interventions, the
laboratory practices that contribute to delays in reporting positive AFB smear results to the specimen submitter should be
further explored.
Delayed laboratory reports for AFB smear-positive patients
were associated with delayed treatment initiation, with 64% of
AFB smear-positive patients with delayed reporting having

delayed treatment. The potential adverse outcomes of delays
in treatment initiation for AFB smear-positive patients include
increased probability of death (9), increased risk of transmission to health care workers and others if the patient is hospitalized and not isolated (12), and increased transmission within
the community. An estimate based on California data available
in 2002 (3) suggests that approximately 268 nonhospitalized
AFB smear-positive pulmonary TB patients had delayed treatment initiation (median treatment delay, 3 days) as a result of
delayed laboratory reporting, 88 contacts of these patients had
to be evaluated by LHDs (0.11 contact exposed per day of
delay [1]), 26 of these contacts had become infected and required treatment for latent TB infection, and 1 contact had TB
disease.
Unlike the findings of previous studies on treatment delays
that pointed to clinical and social factors that are not amenable
to public health intervention (9, 12–14), treatment delays attributable to delays in laboratory reporting of AFB smearpositive results can be addressed by implementing interventions specific to the type of laboratory that is performing the
testing. For example, efforts can be directed to ensuring that
hospital laboratories report smear-positive results within 24 h
of receipt of the specimens.
Health care providers also received delayed laboratory reports of the first evidence of TB for 47% of AFB smearnegative patients in this population. Laboratory reporting delays for AFB smear-negative patients were also associated with
transport delays and laboratory type, with laboratories to
which specimens and cultures were referred (public health and
commercial) having the longest reporting time frames. This
study did not have the power to fully assess other aspects of
referrals between laboratories that may have affected laboratory reporting times, but these may include batching of specimens and less than 7-days-per-week service. Another factor
associated with delays in laboratory reporting to specimen submitters for AFB smear-negative patients was the practice of
reporting the first evidence of TB as positive identification of
M. tuberculosis complex rather than as the presence of AFB in
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a growing culture. This finding suggests that all laboratories
should report the first evidence of AFB in growing culture to
specimen submitters rather than waiting to receive the results
of M. tuberculosis complex identification tests, when confirmation of TB may be reported.
In this study, 77% of AFB smear-negative patients with
laboratory reporting delays had delayed treatment initiation.
Treatment delays for these patients were extremely long, measuring in weeks to months, and may have resulted in clinical
deterioration and increased transmission of TB in the community, and potentially in the hospitals, as 20.7% (23 of 111) of
AFB smear-negative patients with treatment delays were
tested in hospitals.
To address delayed reporting for AFB smear-negative patients, public health efforts should focus on commercial laboratories, which had a median reporting time frame of 31 days,
10 days beyond the recommended 21 days. Of course, a recommended reporting time frame of 21 days is not adequate
when health care providers are waiting to receive culture
results before initiating treatment. The Healthy People 2010
objectives (http://www.healthypeople.gov/document/html
/objectives/14-14.htm) require that the average time for a
laboratory to confirm and report TB cases be reduced to 2
days for 75% of cases. Reaching this objective will decrease
the extent of treatment initiation delays attributable to laboratory reporting delays. One way to reach this objective is
to implement the use of rapid molecular methods by all
laboratories that serve TB patients.
Timely reporting of TB test results to the health care provider is a necessary but not sufficient duty of laboratories.
Laboratory reporting of TB test results to LHDs is required
because it is often the basis for initiating contact investigations
and ensuring that appropriate treatment is begun (7). However, these data showed not only that there was room for
improvement in the completeness and timeliness of reporting
from all non-public health laboratories to LHDs but also that
timely laboratory reporting to LHDs did not always result in
prompt treatment initiation. LHDs should evaluate the effectiveness of their interventions to swiftly act on reports of positive AFB smears and cultures.
One strength of this study was that, unlike previous surveys
of laboratory practice, it was patient based, allowing the linkage of TB patient data from the RVCT to patient-specific
laboratory data. With access to patient data from the RVCT,
this study design allowed the analysis of some previously described risk factors for treatment initiation delays (e.g., age and
chest radiograph results) in addition to laboratory reporting
delays. However, the absence of patient chart data may have
prevented the identification of additional factors associated
with delays in treatment initiation. Also, because the patients
were from California LHDs reporting the largest proportion of
TB cases, the results are not representative of all patients in
California or the United States. It is likely that these findings
underrepresent the extent of the problem of delayed labora-
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tory reporting because the laboratories that serve these four
urban jurisdictions are more densely concentrated and are
likely more proficient in TB testing methods than laboratories
that serve less-urban areas with fewer TB cases.
Our findings reveal the crucial role of laboratory reporting
of TB test results in TB control. To continue to control and
move forward in eliminating TB, it is essential to improve the
timeliness and completeness of laboratory reporting of TB test
results.
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